Annual Report and Accounts

The report records revenue growth of 6.6% to £68.3 million and describes the successful Phase II PQ Grass G205 study, which met its primary endpoint with a statistically significant dose-response relationship. It also describes the Group's corporate responsibility activities across its people, customers, communities and environment. During the year, the Company announced an aim to have 30% female representation on the Board by 2025.